Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 83 points (0.5%) at 16,304 as of Monday, Dec. 23, 2013, 11:55 AM ET. The NYSE advances/declines ratio sits at 2,307 issues advancing vs. 673 declining with 118 unchanged. The Health Care sector currently sits up 1.1% versus the S&P 500, which is up 0.6%. Top gainers within the sector include United Therapeutics Corporation ( UTHR), up 24.1%, Illumina ( ILMN), up 2.3%, Actavis ( ACT), up 2.2%, Vertex Pharmaceuticals ( VRTX), up 2.0% and Humana ( HUM), up 1.7%. TheStreet would like to highlight 3 stocks pushing the sector lower today: 3. Novo Nordisk A/S ( NVO) is one of the companies pushing the Health Care sector lower today. As of noon trading, Novo Nordisk A/S is down $0.94 (-0.5%) to $179.08 on light volume. Thus far, 93,168 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 276,100 shares. The stock has ranged in price between $178.79-$179.78 after having opened the day at $179.56 as compared to the previous trading day's close of $180.02. Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $95.2 billion and is part of the drugs industry. The company has a P/E ratio of 4.0, below the S&P 500 P/E ratio of 17.7. Shares are up 10.1% year to date as of the close of trading on Friday. Currently there is 1 analyst that rates Novo Nordisk A/S a buy, no analysts rate it a sell, and 2 rate it a hold. TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Novo Nordisk A/S Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.